A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention

References

• MeairsSWahlgrenNDirnaglULindvallORothwellPBaronJCStroke research priorities for the next decade – a representative view of the European scientific communityCerebrovasc Dis200622237582
   Web of Science ®Google Scholar
• WHO atlas of heart disease and stroke http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdfAccessed July 8, 2009
   Google Scholar
• TruelsenTPiechowski-JóŸwiakBBonitaRMathersCBogousslavskyJBoysenGStroke incidence and prevalence in Europe: a review of available dataEur J Neurol200613658159816796582
   PubMed Web of Science ®Google Scholar
• PaulSLSrikanthVKThriftAGThe large and growing burden of strokeCurr Drug Targets20078778679317630931
   PubMed Web of Science ®Google Scholar
• GoldsteinLBAdamsRAlbertsMJAppelLJBrassLMBushnellCDAmerican Heart Association; American Stroke Association Stroke CouncilPrimary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working GroupCirculation200611324e873e92316785347
   PubMed Web of Science ®Google Scholar
• Di TullioMRZwasDRSaccoRLSciaccaRRHommaSLeft ventricular mass and geometry and the risk of ischemic strokeStroke200334102380238412958319
   PubMed Web of Science ®Google Scholar
• LüdersSDrug therapy for the secondary prevention of stroke in hypertensive patients: current issues and optionsDrugs200767795596317488141
   PubMed Web of Science ®Google Scholar
• CoullAJLovettJKRothwellPMOxford Vascular StudyPopulation based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of servicesBMJ2004328743532614744823
   PubMedGoogle Scholar
• XuGLiuXWuWZhangRYinQRecurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factorsCerebrovasc Dis20072323117120
   Web of Science ®Google Scholar
• SinghRBSuhILSinghVPChaithiraphanSLaothavornPSyRGHypertension and stroke in Asia: prevalence, control and strategies in developing countries for preventionJ Hum Hypertens2000141011749763
   Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRProspective Studies CollaborationAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• LawesCMVander HoornSRodgersAInternational Society of HypertensionGlobal burden of blood-pressure-related disease, 2001Lancet200837196231513151818456100
   PubMed Web of Science ®Google Scholar
• GorelickPBNew horizons for stroke prevention: PROGRESS and HOPELancet Neurol20021314915612849483
   PubMed Web of Science ®Google Scholar
• ManciaGGrassiGSecondary prevention of stroke: old and new evidenceAging Clin Exp Res200214321622012387531
   PubMed Web of Science ®Google Scholar
• GrassiGArenareFTrevanoFQDell’OroRManciaAGPrimary and secondary prevention of stroke by antihypertensive treatment in clinical trialsCurr Hypertens Rep20079429930417686381
   PubMed Web of Science ®Google Scholar
• StaessenJAWangJGThijsLCardiovascular protection and blood pressure reduction: a meta-analysisLancet200135892901305131511684211
   PubMed Web of Science ®Google Scholar
• LawesCMRodgersABennettDAParagVSuhIUeshimaHAsia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific regionJ Hypertens200321470771612658016
   PubMed Web of Science ®Google Scholar
• LawesCMBennettDAFeiginVLRodgersABlood pressure and stroke: an overview of published reviewsStroke20043541024103315053002
   PubMed Web of Science ®Google Scholar
• GueyffierFBoisselJPBoutitieFPocockSCoopeJCutlerEffect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data Analysis of ANtihypertensive intervention trials) project collaboratorsStroke19972812255725629412649
   PubMedGoogle Scholar
• Breekveldt-PostmaNSPenning-vanBeest FJSiiskonenSJFalveyHVinczeGKlungelOHThe effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and strokeCurr Med Res Opin200824112112718031596
   PubMed Web of Science ®Google Scholar
• PittBByingtonRPFurbergCDHunninghakeDBManciniGBMillerMEEffect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT InvestigatorsCirculation2000102131503151011004140
   PubMed Web of Science ®Google Scholar
• StaessenJAFagardRThijsLCelisHArabidzeGGBirkenhägerWHRandomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial InvestigatorsLancet199735090807577649297994
   PubMed Web of Science ®Google Scholar
• StaessenJAThijsLFagardRHBirkenhägerWHArabidzeGGBabeanuSCalcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertensionHypertension19983234104169740604
   PubMed Web of Science ®Google Scholar
• WangJGStaessenJAGongLLiuLChinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative GroupArch Intern Med2000160221122010647760
   PubMedGoogle Scholar
• LubsenJWagenerGKirwanBAdeBrouwer SPoole-WilsonPAACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigatorsEffect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trialJ Hypertens200523364164815716708
   PubMed Web of Science ®Google Scholar
• DowlatshahiDFangJKawajaMHakimAUse of calcium channel blockers after stroke is not associated with poor outcome: a cohort from the registry of the Canadian stroke networkJ Neurol2006253111478148316786208
   PubMed Web of Science ®Google Scholar
• BangaloreSMesserliFHA review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockersInt J Clin Pract200660101281128616942591
   PubMed Web of Science ®Google Scholar
• StaessenJALiYThijsLWangJGBlood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trialsHypertens Res200528538540716156503
   PubMed Web of Science ®Google Scholar
• VerdecchiaPReboldiGAngeliFGattobigioRBentivoglioMThijsLAngiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke preventionHypertension200546238639216009786
   PubMed Web of Science ®Google Scholar
• DahlöfBSeverPSPoulterNRWedelHBeeversDGCaulfieldMASCOT InvestigatorsPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• PoulterNRWedelHDahlöfBSeverPSBeeversDGCaulfieldMASCOT InvestigatorsRole of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)Lancet2005366948990791316154017
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMLibbyPThompsonPDGhaliMGarzaDCAMELOT InvestigatorsEffect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trialJAMA2004292182217222515536108
   PubMed Web of Science ®Google Scholar
• ALLHAT Collaborative Research GroupMajor outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA2002288232981299712479763
   PubMed Web of Science ®Google Scholar
• LeenenFHNwachukuCEBlackHRCushmanWCDavisBRSimpsonLMALLHAT Collaborative Research GroupClinical events in high-risk hypertensive patients randomily assigned to calcium channel blocker vs angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialHypertension200648337438416864749
   PubMed Web of Science ®Google Scholar
• WangJGLiYFranklinSSSafarMPrevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers. A quantitative overviewHypertension200750118118817502490
   PubMed Web of Science ®Google Scholar
• IadecolaCGorelickPBHypertension, angiotensin, and stroke: beyond blood pressureStroke200435234835014757875
   PubMed Web of Science ®Google Scholar
• SchraderJKulschewskiADendorferAInhibition of the renin-angiotensin system and the prevention of strokeAm J Cardiovasc Drugs200771253717355164
   PubMed Web of Science ®Google Scholar
• BoschJYusufSPogueJSleightPLonnERangoonwalaBHOPE InvestigatorsHeart outcomes prevention evaluation Use of ramipril in preventing stroke: double blind randomised trialBMJ20023247339699702
   Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative GroupRandomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attackLancet200135892871033104111589932
   PubMed Web of Science ®Google Scholar
• FlatherMDYusufSKøberLPfefferMHallAMurrayGLong-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative GroupLancet200035592151575158110821360
   PubMed Web of Science ®Google Scholar
• HanssonLLindholmLHNiskanenLLankeJHednerTNiklasonAEffect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialLancet1999353915361161610030325
   PubMed Web of Science ®Google Scholar
• NiskanenLHednerTHanssonLLankeJNiklasonACAPPP Study GroupReduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta blocker-based treatment regimen: a subanalysis of the Captopril Prevention ProjectDiabetes Care200124122091209611723089
   PubMed Web of Science ®Google Scholar
• BoutitieFOprisiuRAchardJMMazouzHWangJMesserliFHDoes a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin IIJ Hypertens20072581543155317620946
   PubMed Web of Science ®Google Scholar
• EpsteinBJGumsJGCan the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockersPharmacotherapy200525453153915977915
   PubMed Web of Science ®Google Scholar
• FournierAMesserliFHAchardJMFernandezLCerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trialsJ Am Coll Cardiol20044381343134715093864
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSEJuliusSBeeversGde FaireULIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• KjeldsenSEDahlöfBDevereuxRBJuliusSAurupPEdelmanJLIFE (Losartan Intervention for Endpoint Reduction) Study GroupEffects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudyJAMA2002288121491149812243636
   PubMed Web of Science ®Google Scholar
• WachtellKLehtoMGerdtsEOlsenMHHornestamBDahlöfBAngiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) studyJ Am Coll Cardiol200545571271915734615
   PubMed Web of Science ®Google Scholar
• LithellHHanssonLSkoogIElmfeldtDHofmanAOlofssonBSCOPE Study GroupThe Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trialJ Hypertens200321587588612714861
   PubMed Web of Science ®Google Scholar
• The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) InvestigatorsEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensinconverting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• OgiharaTNakaoKFukuiTFukiyamaKUeshimaKObaKCandesartan Antihypertensive Survival Evaluation in Japan Trial GroupEffects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trialHypertension200851239339818172059
   PubMed Web of Science ®Google Scholar
• ONTARGET InvestigatorsYusufSTeoKKPogueJDyalLCoplandITelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• ReboldiGAngeliFCavalliniCGentileGManciaGVerdecchiaPComparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysisJ Hypertens20082671282128918550998
   PubMed Web of Science ®Google Scholar
• SchraderJLüdersSKulschewskiABergerJZidekWTreibJAcute Candesartan Cilexetil Therapy in Stroke Survivors Study GroupThe ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke SurvivorsStroke20033471699170312817109
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [webpage]Scandinavian Candesartan Acute Stroke Tirial (SCAST) [updated 2009 May 13; cited 2008 July 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT00120003
   Google Scholar
• SchraderJLüders SKulschewskiAHammersenFPlateKBergerJMOSES Study GroupMorbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES)Stroke20053661218122615879332
   PubMed Web of Science ®Google Scholar
• DienerHCSaccoRYusufSPRoFESS Study GroupRationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan vs placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS)Cerebrovasc Dis20072356368380
   Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLCottonDOunpuuSLawtonWAPRoFESS Study GroupTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• MesserliFHManciaGContiCRHewkinACKupferSChampionADogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?Ann Intern Med20061441288489316785477
   PubMed Web of Science ®Google Scholar
• CocaAMesserliFHBenetosAZhouQChampionACooper-DeHoffRMPredicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVESTStroke200839234334818162623
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBrunnerHREkmanSHanssonLBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trialLancet200436394262049205115207957
   PubMed Web of Science ®Google Scholar
• ArimaHChalmersJWoodwardMAndersonCRodgersADavisSPROGRESS Collaborative GroupLower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trialJ Hypertens20062461201120816685221
   PubMed Web of Science ®Google Scholar
• MochizukiSDahlöfBShimizuMIkewakiKYoshikawaMTaniguchiIJikei Heart Study groupValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality studyLancet200736995711431143917467513
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMBrunnerHREkmanSHanssonLVALUE trial groupOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet200436394262022203115207952
   PubMed Web of Science ®Google Scholar
• SchmiederREKjeldsenSEJuliusSMcInnesGTZanchettiAHuaTAVALUE Trial GroupReduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialJ Hypertens200826340341118300848
   PubMed Web of Science ®Google Scholar
• TurnbullFBlood Pressure Lowering Treatment Trialists’ CollaborationEffects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsLancet200336293951527153514615107
   PubMed Web of Science ®Google Scholar
• MesserliFHStaessenJAAmlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studiesHypertension200648335936116894055
   PubMed Web of Science ®Google Scholar
• Thone-ReinekeCKrikovMSchmerbachKMullerSVillringerASteckelingsUComparison of the effect of systematic pretreatment with telmisartan, ramipril and their combination on neurological status and infarct volume in rats after strokeJ Hypertens200826Suppl1S118815510
   PubMedGoogle Scholar
• LorenzMWMarkusHSBotsMLRosvallMSitzerMPrediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysisCirculation2007115445946717242284
   PubMed Web of Science ®Google Scholar
• WangJGStaessenJALiYVan BortelLMNawrotTFagardRCarotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trialsStroke20063771933194016763185
   PubMed Web of Science ®Google Scholar
• MörtsellDMalmqvistKHeldCKahanTIrbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) studyJ Intern Med2007261547247917444886
   PubMed Web of Science ®Google Scholar
• OlsenMHWachtellKNelandKBellaJNRokkedalJDige-PetersenHLosartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudyBlood Press200514317718316036498
   PubMed Web of Science ®Google Scholar
• OnoHMinatoguchiSWatanabeKYamadaYMizukusaTKawasakiHCandesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertensionHypertens Res200831227127918360047
   PubMed Web of Science ®Google Scholar
• VerdecchiaPReboldiGGattobigioRBentivoglioMBorgioniCAngeliFAtrial fibrillation in hypertension: predictors and outcomeHypertension200341221822312574085
   PubMed Web of Science ®Google Scholar
• SampsonUKPfefferMAMcMurrayJJLokhnyginaYWhiteHDSolomonSDVALIANT Trial InvestigatorsPredictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT TrialEur Heart J200728668569116984929
   PubMed Web of Science ®Google Scholar
• WattigneyWAMensahGACroftJBIncreasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary preventionCirculation2003108671171612885749
   PubMed Web of Science ®Google Scholar
• KlingbeilAUSchneiderMMartusPMesserliFHSchmiederREA meta-analysis of the effects of treatment on left ventricular mass in essential hypertensionAm J Med20031151414612867233
   PubMed Web of Science ®Google Scholar
• WilliamsBLacyPSThomSMCruickshankKStantonACollierDCAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing CommitteeDifferential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) studyCirculation200611391213122516476843
   PubMed Web of Science ®Google Scholar
• LacyPSWilliamsBImpact of heart rate on the differential impact of blood pressure lowering drugs on central and peripheral pressures: Data from the Conduit Artery Function Evaluation (CAFÉ) studyJ Hypertens200826Suppl1S459
   Google Scholar
• AndoHZhouJMacovaMImbodenHSaavedraJMAngiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive ratsStroke20043571726173115143297
   PubMed Web of Science ®Google Scholar
• NishimuraYItoTSaavedraJMAngiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive ratsStroke200031102478248611022082
   PubMed Web of Science ®Google Scholar
• ItoTYamakawaHBregonzioCTerrónJAFalcón-NeriASaavedraJMProtection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonistStroke20023392297230312215602
   PubMed Web of Science ®Google Scholar
• KumaiYOoboshiHAgoTIshikawaETakadaJKamouchiMProtective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressureExp Neurol2008210244144818177860
   PubMed Web of Science ®Google Scholar
• MogiMIwaiMChenRIwanamiJIdeATsukudaKAmlodipine treatment reduces stroke size in apolipoprotein E-deficient miceAm J Hypertens200619111144114917070425
   PubMed Web of Science ®Google Scholar
• LiuLZhangYLiuGLiWZhangXZanchettiAFEVER Study GroupThe felodipine event reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patientsJ Hypertens200523122157217216269957
   PubMed Web of Science ®Google Scholar
• JamersonKABakrisGLWunCCDahlöfBLefkowitzMManfredaSRationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertensionAm J Hypertens200417979380115363822
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLDahlöfBPittBShiVACCOMPLISH Trial InvestigatorsBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med20083592324172819052124
   PubMed Web of Science ®Google Scholar
• ChalmersJMacMahonSPerindopril protection against recurrent stroke study (PROGRESS): interpretation and implementationJ Hypertens200321SupplS914
   Google Scholar
• ChobanianAVBakrisGLBlackHRCushmanWCGreenLAIzzoJLJrNational Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating CommitteeThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportJAMA2003289192560257212748199
   PubMed Web of Science ®Google Scholar
• ManciaGDe BackerGDominiczakACifkovaRFagardRGermanoG2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens20072561105118717563527
   PubMed Web of Science ®Google Scholar
• SicaDARationale for fixed-dose combination in the treatment of hypertension: the cycle repeatsDrugs200262344346211827559
   PubMed Web of Science ®Google Scholar
• StaessenJAWangJGThijsLCardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003J Hypertens20032161055107612777939
   PubMed Web of Science ®Google Scholar
• DestroMLuckowASamsonMKandraABrunelPEfficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS studyJ Am Soc Hypertens2008229430220409909
   PubMed Web of Science ®Google Scholar
• PhilippTSmithTRGlazerRWernsingMYenJJinJTwo multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertensionClin Ther200729456358017617280
   PubMed Web of Science ®Google Scholar
• SmithTRPhilippTVaisseBBakrisGLWernsingMYenJAmlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studiesJ Clin Hypertens200795355364
   PubMedGoogle Scholar
• PoldermansDGlazesRKargiannisSWernsingMKaczorJChiangYTTolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertensionClin Ther200729227928917472820
   PubMed Web of Science ®Google Scholar
• BrixnerDIJacksonKC2ndShengXNelsonREKeskinaslanAAssessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinationsCurr Med Res Opin20082492597260718812017
   PubMed Web of Science ®Google Scholar